Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Treasury Shares (2017 - 2025)

Coherus Oncology (CHRS) has disclosed Treasury Shares for 11 consecutive years, with $188557.0 as the latest value for Q4 2025.

  • Quarterly Treasury Shares fell 75.46% to $188557.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $188557.0 through Dec 2025, down 75.46% year-over-year, with the annual reading at $188557.0 for FY2025, 75.46% down from the prior year.
  • Treasury Shares hit $188557.0 in Q4 2025 for Coherus Oncology, down from $768237.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $2.3 million in Q4 2022 to a low of $188557.0 in Q4 2025.
  • Historically, Treasury Shares has averaged $1.4 million across 5 years, with a median of $1.7 million in 2023.
  • Biggest five-year swings in Treasury Shares: soared 82.61% in 2021 and later plummeted 75.46% in 2025.
  • Year by year, Treasury Shares stood at $1.8 million in 2021, then grew by 26.55% to $2.3 million in 2022, then dropped by 26.0% to $1.7 million in 2023, then crashed by 55.51% to $768237.0 in 2024, then tumbled by 75.46% to $188557.0 in 2025.
  • Business Quant data shows Treasury Shares for CHRS at $188557.0 in Q4 2025, $768237.0 in Q4 2024, and $1.7 million in Q4 2023.